News & Press

• Archive

• Pharmaceutical Products

  5/19/2011 8:03:00 AM

  Study Characterizes Extractability Properties of Once-Daily Extended-Release Hydromorphone

  Properties of OROS(R) technology also shown to provide predictable, consistent blood plasma levels of hydromorphone at steady-state, reducing peaks and troughs AUSTIN, Texas, May 19, 2011 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products, announced the results of two studies that compare the physical and pharmaco…

• Imaging Products

  3/10/2011 8:07:00 AM

  Covidien Receives FDA Approval for South African-Produced Medical Isotope Based on Low-Enriched Uranium

  ST. LOUIS, Mar 10, 2011 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of molybdenum-99 (Mo-99) derived from low-enriched uranium (LEU) in the production of technetium-99m (Tc-99m) generators. Tc-99m is a medical isotope, utilized in over 80% of all nuclear medicine studies, supplied to hospitals and nuclear pharmacies by …

• Covidien

  11/15/2011 6:00:00 AM

  Covidien Reports Fourth-Quarter and Fiscal 2011 Results

  View PDF Fourth-quarter net sales up 15%; Medical Devices sales up 18% Fourth-quarter diluted GAAP earnings per share from continuing operations were $0.93; excluding specified items, adju…

• 11/9/2011 7:00:00 AM

  Covidien to Present at Lazard Healthcare Conference

  MANSFIELD, Mass., Nov 09, 2011 (BUSINESS WIRE) -- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Lazard Capital Markets Healthcare Conference in New York on November 16, 2011. Coleman N. Lannum, Vice President, Investor Relations, will discuss the Company in a presentation scheduled to begin at 1:30PM ET. …